Research ArticleARRHYTHMOGENIC CARDIOMYOPATHY

Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy

See allHide authors and affiliations

Science Translational Medicine  12 Feb 2020:
Vol. 12, Issue 530, eaay8329
DOI: 10.1126/scitranslmed.aay8329

Log in to view PDF

Log in through your institution

Log in through your institution

Stay Connected to Science Translational Medicine